key: cord-1028042-3os6sfro
authors: Finn, Avni P.; Khurana, Rahul N.; Chang, Louis K.
title: Hemi-retinal vein occlusion in a young patient with COVID-19
date: 2021-03-05
journal: Am J Ophthalmol Case Rep
DOI: 10.1016/j.ajoc.2021.101046
sha: 5ad3e228dee30655aad4c7411bf04dd792629aae
doc_id: 1028042
cord_uid: 3os6sfro

PURPOSE: To report a case of a hemi-retinal vein occlusion (HRVO) in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). OBSERVATIONS: A 32-year-old healthy male presented with a paracentral scotoma, retinal hemorrhages, and dilated and tortuous retinal vessels inferiorly in the right eye. He was diagnosed with HRVO in the setting of recent SARS-CoV-2 infection. CONCLUSIONS AND IMPORTANCE: Venous thromboembolic complications and coagulation abnormalities have been widely reported in association with SARS-CoV-2 infection. We highlight this case to raise awareness that a retinal vein occlusion in an otherwise healthy, young patient may be a potential manifestation of the thromboinflammatory state associated with SARS-CoV-2 infection.

Hemi-retinal vein occlusion (HRVO) is a variant of central retinal vein occlusion (CRVO) with hypercoagulability thought to be a risk factor, especially in younger patients. 1 Abnormal hematologic parameters and an increased risk of venous thromboembolism are common among patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2, 3 We report a case of a young patient with a HRVO in the setting of SARS-CoV-2 infection.

A 32-year-old previously healthy male with fevers, cough, fatigue, and anosmia was diagnosed with SARS-CoV-2 infection with positive reverse transcriptase polymerase chain reaction (RT-PCR) testing from a nasopharyngeal swab. He was referred by his primary care doctor as he reported mild blurriness in his superior visual field in his right eye. The blurring was only present when looking at a light background and had been present for about two weeks. His visual acuity was 20/20 in both eyes and an initial dilated fundus examination was unremarkable. No further diagnostic imaging, including invasive testing such as fluorescein angiography, was performed to limit exposure to other patients and personnel in the clinic given his active infection. Two subsequent RT-PCR tests were positive, followed by two consecutive negative RT-PCR tests and the development of detectable serum IgG antibodies to SARS-CoV-2 about seven weeks after initial symptoms onset. He remained normotensive during and after the time of his illness with SARS-CoV-2.

One month after his initial examination, he reported worsening symptoms with sudden onset paracentral scotoma in his right eye and was evaluated the same day. On examination, his visual acuity remained 20/20 in both eyes. Dilated fundus examination of the right eye showed rare scattered hemorrhages in the inferior hemisphere and dilated and tortuous vessels inferiorly ( Figure 1A ). Fundus examination of the left eye appeared normal. Fluorescein angiography showed marked delay in filling of the inferior venous circulation (Figure 1B-C) with late staining of those vessels OD ( Figure 1D ). Optical coherence tomography of the macula showed no evidence of central macular edema OU, but there was mild thickening and increased hyperreflectivity of the outer plexiform layer nasally OD, corresponding to the patient's scotoma ( Figure 2 ).

HRVO and CRVO are believed to result from thrombus formation near the lamina cribosa. 1 Classic risk factors include hypertension, cardiovascular disease, glaucoma, and diabetes mellitus. In younger patients without these risk factors, laboratory testing for clotting disorders may be considered; however, an extensive workup for thrombophilia risk factors is often negative. 4 Most retina specialists only consider thrombophilia testing for select cases, such as patients with a personal history of thrombosis, family history of thrombosis at a young age, or an unusual presentation.

Indeed, in our patient, laboratory work up including PT, PTT, CBC, anti-cardiolipin antibodies, lupus anticoagulant, Factor V Leiden, protein C and S testing was unremarkable.

In patients with SARS-CoV-2, there is an increased propensity for thromboembolic complications, including both arterial and venous thrombotic events. 5,6 Individuals with SARS-CoV-2 infection may have a number of coagulation abnormalities suggesting a hypercoagulable state, which has been called COVID-19 associated coagulopathy. 3 Various studies of patients hospitalized with severe COVID-19 infection have significant rates of venous thromboembolic events, including deep venous thrombosis, pulmonary embolism, and catheter-associated thrombosis. Additionally, there have been reports of arterial thrombosis including stroke, limb ischemia, and heart attacks. 3, 7 Thrombotic events occurred in about 16% of hospitalized patients according to one study of New York City hospital systems. 6 While there is limited data in the outpatient setting, SARS-CoV-2 patients may be at risk of venous thromboembolic events, potentially for an extended period of time after acute illness. 8 Although this patient did not experience a generalized, systemic cytokine storm associated with more severe disease, milder endothelial damage may increase the risk for thrombosis even after the acute infection. 8 Prior studies have demonstrated an association between pro-inflammatory cytokines and onset of venous thromboembolism, suggesting inflammation from recent infection may contribute to thromboembolic risk. 9 Researchers postulate that COVID-19 may further elevate this risk given the abnormalities in hematologic markers of coagulation seen with viral infection from COVID-19. 2, 3 In hospitalized patients with coagulopathy, lab abnormalities include modest prolongation of prothrombin times in about 5% of patients, mild thrombocytopenia in approximately 30% of patients, and elevated Ddimer values in 43%-60% of patients. 10, 11 Of note, D-dimer, fibrinogen, and platelets were within normal limits at the time of this patient's second presentation with more severe ocular symptoms and evidence of vein occlusion. However, this was about two months after the onset of acute infection, which was managed as an outpatient given his relatively mild respiratory symptoms.

Though we acknowledge the increasing seroprevalence of SARS-CoV-2 infection, especially among younger patients, and while a causal relationship cannot be established; it is plausible that HRVO in an otherwise healthy, young patient may be a manifestation of a thromboinflammatory state associated with SARS-CoV-2 infection. We highlight this case so that patients with visual symptoms may be properly evaluated and to raise awareness of the potential association of this pandemic infection with retinal venous thromboembolism. 

Hemi-Central Retinal Vein Occlusion: Pathogenesis, Clinical Features, and Natural History

Haematological manifestations in patients with severe acute respiratory syndrome: Retrospective analysis

COVID-19 and its implications for thrombosis and anticoagulation

Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age

COVID-19 update: Covid-19-associated coagulopathy

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

COVID-19 and hypercoagulability in the outpatient setting

Venous thromboembolism in the outpatient setting

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Coagulation abnormalities and thrombosis in patients with COVID-19

_Avni Finn

[Instructions: Please check all applicable boxes and provide additional information as requested.]

Potential conflict of interest exists:We wish to draw the attention of the Editor to the following facts, which may be considered as potential conflicts of interest, and to significant financial contributions to this work:The nature of potential conflict of interest is described below:No conflict of interest exists.We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

No funding was received for this work.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.IRB approval was obtained (required for studies and series of 3 or more cases) Written consent to publish potentially identifying information, such as details or the case and photographs, was obtained from the patient(s) or their legal guardian(s).This case report was exempt from IRB approval. Written consent to publish the case report was not obtained. This report does not contain any personal information that could lead to the identification of the patient.

The International Committee of Medical Journal Editors (ICMJE) recommends that authorship be based on the following four criteria:1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND 2. Drafting the work or revising it critically for important intellectual content; AND 3. Final approval of the version to be published; AND 4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. For more information on authorship, please see http://www.icmje.org/recommendations/browse/roles-andresponsibilities/defining-the-role-of-authors-and-contributors.html#two.All listed authors meet the ICMJE criteria. We attest that all authors contributed significantly to the creation of this manuscript, each having fulfilled criteria as established by the ICMJE.We confirm that the manuscript has been read and approved by all named authors.We confirm that the order of authors listed in the manuscript has been approved by all named authors.

The Corresponding Author declared on the title page of the manuscript is:

This author submitted this manuscript using his/her account in EVISE.We understand that this Corresponding Author is the sole contact for the Editorial process (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.